Article
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
Nature communications - 22 Jun 2020
Fernandes Neto João M, Nadal Ernest, Bosdriesz Evert, Ooft Salo N, Farre Lourdes, McLean Chelsea, Klarenbeek Sjoerd, Jurgens Anouk, Hagen Hannes, Wang Liqin, Felip Enriqueta, Martinez-Marti Alex, Vidal August, Voest Emile, Wessels Lodewyk F A, van Tellingen Olaf, Villanueva Alberto, Bernards René
Abstract excerpt
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.